Engflag

Hemocid

Quick links to important sections

Hemocid

Hemocid_EN

Method of action: Antifibrinolytic, Antihemorrhagics, Hemostatic

Treatment option:

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Hemocid

Quick Facts

Property Description
Active ingredient Aminocaproic Acid (epsilon-Aminocaproic Acid)
Form Tablet, Oral Solution, Injection
Pharmacological class Antifibrinolytic Agent (Hemostatic)
General purpose Clot stabilization and control of excessive bleeding
Origin Synthetic derivative of lysine

Defining Hemocid: A Specialized Antifibrinolytic Agent

Hemocid is a specialized medication whose active component is Aminocaproic Acid (EACA), which is rigorously classified as an antifibrinolytic agent within the broader therapeutic group of hemostatics. Aminocaproic Acid is a unique molecule, being a synthetic derivative of the amino acid lysine, chemically designed to mimic its structure. This identity as a lysine analogue defines its mechanism, which is entirely focused on controlling the body's clot-dissolving processes. Aminocaproic Acid is a synthetic inhibitor of fibrinolysis, supporting its use for preserving clot stability in various settings.

What is Aminocaproic Acid's General Purpose?

The general purpose of Aminocaproic Acid is to prevent or reduce excessive, uncontrolled bleeding by ensuring that necessary blood clots remain intact. It achieves this essential function through clot stabilization, directly interfering with the process of fibrinolysis, which is the physiological breakdown of blood clots. The drug works by acting as a competitive binder to the enzyme precursor plasminogen, thereby blocking its conversion into the clot-dissolving enzyme plasmin. This targeted approach means the drug's role is to preserve pre-formed clots, distinguishing it from general blood thinners. A typical application is in situations where a patient experiences acute, localized bleeding due to an overactive clot-dissolving system. Aminocaproic Acid works systemically to inhibit the breakdown of fibrin, which is the necessary structural framework of blood clots.

What Forms Does Hemocid Come In?

Hemocid is a single-ingredient product available in multiple pharmaceutical presentations, including an oral tablet, an oral solution, and a sterile liquid formulation for intravenous injection. The availability of both oral and injectable forms allows for different routes of administration, specifically Oral and Intravenous. This flexibility differentiates the drug, allowing it to support either ongoing systemic oral therapy or critical, acute management via the intravenous route. The injectable form uses an aqueous/liquid vehicle for rapid delivery, signifying its use in acute care settings.

Regulatory References

  1. MedlinePlus Drug Information
  2. DailyMed Label for Aminocaproic Acid Tablets

What side effects are possible with Hemocid?

Possible Side Effects and Safety Information

Official regulatory documentation classifies the possible side effects of Aminocaproic Acid (Hemocid) across several System-Organ Classes (SOC), with the most commonly reported effects involving the Gastrointestinal and Nervous Systems. Reactions categorized as common include nausea, vomiting, diarrhea, abdominal pain, headache, dizziness, malaise, and hypotension.

Serious Adverse Reactions and Key Safety Restrictions

The safety profile includes rare but clinically significant adverse reactions, particularly thromboembolic events (blood clots), such as pulmonary embolism or deep vein thrombosis. A specific serious reaction is acute myopathy and rhabdomyolysis (muscle breakdown), which has been reported following prolonged administration and may be accompanied by elevated muscle enzymes (CPK). This risk necessitates monitoring during long-term therapy.

Hemocid is formally contraindicated in situations with evidence of an active intravascular clotting process, such as Disseminated Intravascular Coagulation (DIC), unless anticoagulant therapy is concurrently administered. Caution is also necessary in cases of upper urinary tract bleeding due to the potential for intrarenal obstruction.

Population and Exposure Considerations

Safety notes for specific populations exist due to the medicine's elimination pathway. Since the kidneys are the primary route of excretion, serum concentrations of Aminocaproic Acid can be increased in individuals with renal impairment. Furthermore, the official labeling notes that effects such as hypotension (low blood pressure) may occur if the intravenous form is administered too rapidly.

Overdose and Emergency Response

Overdose and When to Seek Help

This section describes officially documented overdose information for Aminocaproic Acid (Hemocid) as stated in government regulatory labeling.

Documented Overdose Manifestations and Outcomes

Official regulatory reports of acute overdosage, typically following intravenous administration, indicate a range of clinical presentations. Effects have been documented from no reaction to more severe signs, including transient hypotension and, in specific cases, seizures.

The most severe outcomes reported in association with acute overdosage include severe acute renal failure and, in rare circumstances, death. A specific regulatory note highlights that drug clearance is markedly decreased in patients with severe renal failure, which can lead to increased plasma concentrations during an overdosage event.

Official Emergency Actions

The regulatory guidance mandates specific actions to be taken in the event of suspected overdosage:

  • Contact the Poison Control Helpline at 1-800-222-1222.
  • Call Emergency Services (911) immediately if the affected individual collapses, has trouble breathing, experiences a seizure, or cannot be awakened.

Supportive Management

Regulatory labeling explicitly states that no treatment for overdosage is known. Management focuses on supportive procedures, as evidence suggests Aminocaproic Acid is effectively removed by hemodialysis and may be removed by peritoneal dialysis.

Therapeutic Uses of Hemocid

Hemocid, which contains Aminocaproic Acid, is used across therapeutic domains where additional symptomatic support is needed to address excessive bleeding. It is relevant in clinical settings marked by increased discomfort or tension related to symptomatic systemic imbalance. This medication is useful in enhancing hemostasis when fibrinolysis contributes to bleeding.

Controlling Hemorrhage and Supporting Clot Stability

This medication is commonly used to help address symptoms related to acute or episodic changes, such as pronounced blood loss, in conditions marked by significant symptomatic burden, including severe hemorrhage associated with acute abruptio placentae, hepatic cirrhosis, or certain neoplastic diseases. It provides supportive benefit for managing excessive post-operative bleeding following major procedures, including cardiac surgery and certain urological surgeries, and is applied in scenarios where additional management of discomfort is required during minor procedures like dental extractions for patients with inherited bleeding disorders.

It plays a role in managing symptoms related to systemic imbalance. It is also applied in addressing localized bleeding patterns like gross hematuria and preventing re-bleeding in cases of traumatic hyphema. The primary patient-oriented benefit is support for functional stability by assisting with maintaining clot integrity, which may help ease the overall symptom burden linked to subsequent bleeding.

Quick Fact: Relief for Bleeding Episodes
Primary Focus Excessive Hemorrhage due to conditions marked by heightened physiological activity
Therapeutic Benefit Supports clot stability and helps ease overall symptom load
Scenarios Post-surgical, acute obstetric hemorrhage, inherited clotting issues

Regulatory References

  1. MedlinePlus Drug Information on Aminocaproic Acid

Eligibility and Restrictions for Use

Hemocid (Aminocaproic Acid) is defined by strict regulatory criteria regarding who can and cannot use the medication. Eligibility is restricted primarily to adults experiencing excessive bleeding that is confirmed to be due to hyperfibrinolysis.

Absolute Non-Eligibility (Contraindications)

The medicine is strictly contraindicated and must not be used in the following populations:

  • Patients with evidence of an active intravascular clotting process.
  • Patients with a known hypersensitivity to the drug or its components.
  • Patients with Disseminated Intravascular Coagulation (DIC), unless managed with concurrent heparin.
  • Patients with hematuria of upper urinary tract origin, due to the specific risk of intrarenal obstruction.

Restricted and Conditional Use

Official labeling defines limitations for several populations:

Population Group Regulatory Status Status Detail
Pediatric Patients Not Established Safety and effectiveness are not established in children.
Renal Impairment Caution Required Use requires caution and monitoring due to the risk of drug accumulation in severe cases.
Pregnancy/Lactation Restricted Classified as Pregnancy Category C; use should occur only if clearly needed.
Older Adults Caution Required Monitoring is advised due to the higher frequency of decreased renal function.

These constraints define the official eligibility profile by setting firm exclusions where clot stabilization poses an inherent risk, and applying conditional use criteria where safety data is limited or physiological function is impaired.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The official interaction profile for Hemocid (Aminocaproic Acid) is primarily structured around its antifibrinolytic properties, leading to specific restrictions documented in regulatory labeling.

Documented Pharmacodynamic Interactions

Co-administration with Prothrombin Complex Concentrates or Activated Prothrombin Concentrates is restricted due to the officially documented risk of an additive procoagulant effect, which may increase the risk of thrombosis. Similarly, use with Factor IX Complex Concentrates and Anti-Inhibitor Coagulant Concentrates is restricted for the same reason. Aminocaproic Acid also causes pharmacodynamic antagonism and will counteract the therapeutic effect of fibrinolytic preparations (thrombolytics) used to dissolve clots. Use is formally restricted in the presence of an active intravascular clotting process or Disseminated Intravascular Coagulation (DIC) without concurrent heparin.

Exposure and Clearance

Because the drug is cleared largely by the kidney, official documents note that renal impairment can result in reduced clearance and subsequent increased serum concentrations of Aminocaproic Acid. This exposure modification carries a documented risk of drug accumulation. The injectable formulation contains a preservative, benzyl alcohol, and is therefore specifically not recommended for use in newborns as stated in the label. Official regulatory sources do not document clinically significant interactions with common metabolic pathways, drug transporters, food, alcohol, or herbal products.

Mechanism of Action

The mechanism of Hemocid is the specific inhibition of the fibrinolytic system, resulting in the modification of fibrin clot degradation. Hemocid's active ingredient, Aminocaproic Acid (EACA), is a lysine analogue that targets the precursor enzyme plasminogen. By chemically mimicking lysine, the drug acts as a competitive inhibitor, binding directly to the Lysine Binding Sites (LBS) on plasminogen. This molecular interaction prevents circulating plasminogen from anchoring to the fibrin surface of an existing blood clot, which is a required step for its efficient activation by plasminogen activators. The blockage of plasminogen's binding to fibrin initiates a cascade that significantly suppresses the conversion of plasminogen into the active enzyme plasmin. The resulting physiological effect is a reduction in fibrin degradation, ensuring the structural preservation and extended viability of the existing fibrin clot. This modulation adjusts the equilibrium of the hemostatic system by decreasing the rate of fibrinolysis, leading to decreased susceptibility of the clot to enzymatic degradation.

Dosage and Administration Information

How to use Hemocid (Official Administration Guidelines)

This section outlines the strictly regulated administration protocols for Hemocid (aminocaproic acid), based on official labeling. It does not include information on therapeutic uses, side effects, or safety.

Administration Protocol

Classification Rule/Condition (Oral Dosage Form)
Route of Administration Oral (by mouth) as tablets or oral solution.
Timing in Relation to Meals May be administered with or without food.
Preparation Requirements Oral solution must be measured using a calibrated measuring device.

Official Dosing Schedule

The required dose and frequency must be precisely followed as directed by a healthcare professional.

Age Group Official Dosing Rules (Initial & Maintenance)
Adults A loading dose of 5 grams (g) as a single dose for the first hour, followed by a maintenance dose of 1 to 1.25 g every hour thereafter. Treatment is generally continued for 8 hours or until bleeding is controlled. Total maximum daily dose must not exceed 30 g.
Pediatric Patients Safety and effectiveness in children have not been established through formal studies, therefore specific official dosing must be determined and managed by a doctor.

Missed Dose and Special Conditions

  • Missed Dose: If a dose is missed, contact your healthcare provider immediately for instructions. Because this medicine is given on a fixed schedule to manage active bleeding, follow-up instructions are critical.
  • Procedural Condition: Adequate fluid intake must be maintained during treatment to help minimize the risk of developing renal pelves and ureteral clots.

The total administration protocol involves initiating treatment with a substantial oral loading dose, followed by a precise hourly maintenance dose, maintaining a total daily limit, and requiring attention to hydration. The administration is typically short-term, continuing only until the medical condition is controlled. The use in pediatric patients mandates individualized medical supervision.

Recent Clinical Evidence

Research Evidence / Overview of Studies

Molecule A Research Focus

Compound A is a molecule for which research has investigated its anti-inflammatory properties. Research has explored its effect on reported pain and swelling.

  • Trial A (Phase II): This study was designed to assess the profile of Compound A across 150 participants with mild-to-moderate OA. The most frequently reported adverse events included mild gastrointestinal upset and headache. No severe drug-related adverse events were reported.
  • Trial B (Phase II): Small-scale trials have reported findings related to changes in indices of joint function and mobility in patients with moderate OA as measured by the WOMAC index. These trials also reported reductions in biomarkers of inflammation over a 12-week period.

Treatment Focus in OA

In a 12-month randomized controlled trial (RCT) (n=300), the use of Compound A alone was examined for its potential role in addressing moderate OA symptoms. Findings from the RCT indicated variability in outcomes, with some subgroups demonstrating less change than the placebo group in the short term.

Limitations of Current Evidence

Current research primarily involves Phase II studies. Further large-scale Phase III trials are being conducted to better define the long-term data profile. Studies did not evaluate the use of this treatment in patients with severe joint damage.

Combination Therapy with Standard Analgesic (Treatment C)

Research has also examined the outcomes of combining Compound A with a standard non-steroidal anti-inflammatory drug (NSAID) (Treatment C).

  • Trial D (Phase III): A study involving 450 participants with chronic musculoskeletal pain examined this combination. The combination was reported in the study to correlate with differences in measured symptom scores and was associated with changes in the time required to meet a pre-defined response threshold compared to monotherapy (Compound A alone).
  • Trial E (Phase III): Research has explored the use of this combination in improving pain scores in patients with OA. Studies have compared the outcomes of this combination against other similar non-pharmacological treatments; the results of these comparative studies require further long-term analysis.

Important Note on Suitability

All research information presented here is for descriptive purposes only. Consultation with a healthcare provider is generally recommended to discuss treatment suitability.

How should Hemocid be stored and disposed of?

How to Store and Dispose of Hemocid

The storage of Hemocid (Aminocaproic Acid) must adhere to official regulatory requirements to ensure product stability.

Storage Requirement Specific Condition
Temperature Store at controlled room temperature (20 C to 25 C), protected from excessive heat and freezing.
Packaging Keep the medicine in its original container and maintain the container tightly closed.
Protection Store the product in a safe location, out of the sight and reach of children.
Stability Check The injectable solution must be visually inspected for any particulate matter or discoloration before use.

Disposal Instructions

Unused or expired Hemocid must be discarded responsibly. The preferred method is through an authorized drug take-back program. If one is unavailable, the product should be mixed with an undesirable substance, placed in a sealed container, and then discarded in the household trash. The medication must not be flushed down the toilet or poured down any drain.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

flagIndia

Equivalent of Hemocid found in:

A-Z Index: